Advertisement

Hormones

, Volume 18, Issue 1, pp 65–70 | Cite as

Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview

  • Dimitrios A. Anastasilakis
  • Polyzois Makras
  • Stergios A. Polyzos
  • Athanasios D. AnastasilakisEmail author
  • Part of the COMBO ENDO TEAM: 2017
Review Article

Abstract

Asymptomatic primary hyperparathyroidism (PHPT) and the new variant of PHPT, normocalcemic PHPT, are considered by many physicians as mild, innocuous forms of disease, requiring nothing more than monitoring. Although this may be true in some cases in which the disease does not progress or cause complications, deterioration with more or less severe manifestations may occur. In the present review, we discuss the existing evidence of both the classic (skeletal and renal) and non-classic (cardiovascular, gastrointestinal, and psychiatric) features that have been attributed to asymptomatic and normocalcemic PHPT and the treatment effect on them.

Keywords

Asymptomatic Bone Hyperparathyroidism Normocalcemic Renal 

Notes

Compliance with ethical standards

The authors declare that they have no conflict of interest.

References

  1. 1.
    Bilezikian JP, Khan AA, Potts JT Jr (2009) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 94:335–339CrossRefGoogle Scholar
  2. 2.
    Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ (2007) Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 92:3001–3005CrossRefGoogle Scholar
  3. 3.
    Silverberg SJ, Bilezikian JP (2003) “Incipient” primary hyperparathyroidism: a “forme fruste” of an old disease. J Clin Endocrinol Metab 88:5348–5352CrossRefGoogle Scholar
  4. 4.
    Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Rubin MR (2009) Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:351–365CrossRefGoogle Scholar
  5. 5.
    Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM et al (2013) Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 98:2734–2741CrossRefGoogle Scholar
  6. 6.
    Maruani G, Hertig A, Paillard M, Houillier P (2003) Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88:4641–4648CrossRefGoogle Scholar
  7. 7.
    Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L et al (2017) Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporosis International : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 28:1–19CrossRefGoogle Scholar
  8. 8.
    Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, Thakker RV (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99:3570–3579CrossRefGoogle Scholar
  9. 9.
    Cromer MK, Starker LF, Choi M, Udelsman R, Nelson-Williams C, Lifton RP et al (2012) Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. J Clin Endocrinol Metab 97:E1774–E1781CrossRefGoogle Scholar
  10. 10.
    Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C et al (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99:3561–3569CrossRefGoogle Scholar
  11. 11.
    Makras P, Anastasilakis AD (2018) Bone disease in primary hyperparathyroidism. Metabolism 80:57–65CrossRefGoogle Scholar
  12. 12.
    Christiansen P, Steiniche T, Brixen K, Hessov I, Melsen F, Charles P et al (1997) Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. Bone 21:93–99CrossRefGoogle Scholar
  13. 13.
    Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E et al (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462–3470CrossRefGoogle Scholar
  14. 14.
    Cipriani C, Biamonte F, Costa AG, Zhang C, Biondi P, Diacinti D et al (2015) Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology. J Clin Endocrinol Metab 100:1309–1315CrossRefGoogle Scholar
  15. 15.
    Walker MD, Silverberg SJ (2018) Primary hyperparathyroidism. Nat Rev Endocrinol 14:115–125CrossRefGoogle Scholar
  16. 16.
    Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F (2012) Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012:128352CrossRefGoogle Scholar
  17. 17.
    Tay YD, Liu M, Bandeira L, Bucovsky M, Lee JA, Silverberg SJ et al (2018) Occult urolithiasis in asymptomatic primary hyperparathyroidism. Endocr Res 43:106–115CrossRefGoogle Scholar
  18. 18.
    Yu N, Donnan PT, Leese GP (2011) A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol 75:169–176CrossRefGoogle Scholar
  19. 19.
    Walker MD, Silverberg SJ (2008) Cardiovascular aspects of primary hyperparathyroidism. J Endocrinol Investig 31:925–931CrossRefGoogle Scholar
  20. 20.
    Aktas Yilmaz B, Akyel A, Kan E, Ercin U, Tavil Y, Bilgihan A et al (2013) Cardiac structure and functions in patients with asymptomatic primary hyperparathyroidism. J Endocrinol Investig 36:848–852Google Scholar
  21. 21.
    Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G et al (2007) Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 92:3114–3121CrossRefGoogle Scholar
  22. 22.
    Bollerslev J, Jansson S, Mollerup CL, Nordenstrom J, Lundgren E, Torring O et al (2007) Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 92:1687–1692CrossRefGoogle Scholar
  23. 23.
    Rao DS, Phillips ER, Divine GW, Talpos GB (2004) Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab 89:5415–5422CrossRefGoogle Scholar
  24. 24.
    Eller-Vainicher C, Filopanti M, Palmieri S, Ulivieri FM, Morelli V, Zhukouskaya VV et al (2013) Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur J Endocrinol 169:155–162CrossRefGoogle Scholar
  25. 25.
    Hansen S, Hauge EM, Rasmussen L, Jensen JE, Brixen K (2012) Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography. J Bone Miner Res 27:1150–1158CrossRefGoogle Scholar
  26. 26.
    Lundstam K, Heck A, Mollerup C, Godang K, Baranowski M, Pernow Y et al (2015) Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. J Clin Endocrinol Metab 100:1359–1367CrossRefGoogle Scholar
  27. 27.
    Lundstam K, Heck A, Godang K, Mollerup C, Baranowski M, Pernow Y et al (2017) Effect of surgery versus observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH study). J Bone Miner Res 32:1907–1914CrossRefGoogle Scholar
  28. 28.
    Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O'Fallon W, Riggs B (1999) Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14:1700–1707CrossRefGoogle Scholar
  29. 29.
    Zanocco KA, Wu JX, Yeh MW (2017) Parathyroidectomy for asymptomatic primary hyperparathyroidism: a revised cost-effectiveness analysis incorporating fracture risk reduction. Surgery 161:16–24CrossRefGoogle Scholar
  30. 30.
    Rejnmark L, Vestergaard P, Mosekilde L (2011) Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 96:2377–2385CrossRefGoogle Scholar
  31. 31.
    Iwata S, Walker MD, Di Tullio MR, Hyodo E, Jin Z, Liu R et al (2012) Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab 97:132–137CrossRefGoogle Scholar
  32. 32.
    Walker MD, Rundek T, Homma S, DiTullio M, Iwata S, Lee JA et al (2012) Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism. Eur J Endocrinol 167:277–285CrossRefGoogle Scholar
  33. 33.
    Farahnak P, Ring M, Caidahl K, Farnebo LO, Eriksson MJ, Nilsson IL (2010) Cardiac function in mild primary hyperparathyroidism and the outcome after parathyroidectomy. Eur J Endocrinol 163:461–467CrossRefGoogle Scholar
  34. 34.
    Nilsson IL, Aberg J, Rastad J, Lind L (1999) Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 126:1049–1055CrossRefGoogle Scholar
  35. 35.
    McMahon DJ, Carrelli A, Palmeri N, Zhang C, DiTullio M, Silverberg SJ et al (2015) Effect of parathyroidectomy upon left ventricular mass in primary hyperparathyroidism: a meta-analysis. J Clin Endocrinol Metab 100:4399–4407CrossRefGoogle Scholar
  36. 36.
    Talpos GB, Bone HG 3rd, Kleerekoper M, Phillips ER, Alam M, Honasoge M et al (2000) Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey. Surgery 128:1013–1020 discussion 20–1CrossRefGoogle Scholar
  37. 37.
    Espiritu RP, Kearns AE, Vickers KS, Grant C, Ryu E, Wermers RA (2011) Depression in primary hyperparathyroidism: prevalence and benefit of surgery. J Clin Endocrinol Metab 96:E1737–E1745CrossRefGoogle Scholar
  38. 38.
    Kahal H, Aye M, Rigby AS, Sathyapalan T, England RJ, Atkin SL (2012) The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism. Clin Endocrinol 76:196–200CrossRefGoogle Scholar
  39. 39.
    Walker MD, McMahon DJ, Inabnet WB, Lazar RM, Brown I, Vardy S et al (2009) Neuropsychological features in primary hyperparathyroidism: a prospective study. J Clin Endocrinol Metab 94:1951–1958CrossRefGoogle Scholar
  40. 40.
    Roman SA, Sosa JA, Pietrzak RH, Snyder PJ, Thomas DC, Udelsman R et al (2011) The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism. Ann Surg 253:131–137CrossRefGoogle Scholar
  41. 41.
    Tsvetov G, Hirsch D, Shimon I, Benbassat C, Masri-Iraqi H, Gorshtein A et al (2017) Thiazide treatment in primary hyperparathyroidism-a new indication for an old medication? J Clin Endocrinol Metab 102:1270–1276Google Scholar
  42. 42.
    Eller-Vainicher C, Palmieri S, Cairoli E, Goggi G, Scillitani A, Arosio M et al (2018) Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J Am Geriatr Soc 66:518–524CrossRefGoogle Scholar
  43. 43.
    Somnay YR, Craven M, McCoy KL, Carty SE, Wang TS, Greenberg CC et al (2017) Improving diagnostic recognition of primary hyperparathyroidism with machine learning. Surgery 161:1113–1121CrossRefGoogle Scholar
  44. 44.
    Tuna MM, Caliskan M, Unal M, Demirci T, Dogan BA, Kucukler K et al (2016) Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J Bone Miner Metab 34:331–335CrossRefGoogle Scholar
  45. 45.
    Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E et al (2013) Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 98:3213–3220CrossRefGoogle Scholar
  46. 46.
    Mokrysheva N, Mirnaya S, Eremkina A, Krupinova J, Kovaleva E (2017) Normocalcemic versus hypercalcemic primary hyperparathyroidism: a comparative study. Endocr Abstr 49:EP257Google Scholar
  47. 47.
    Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H et al (2015) Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 100:2420–2424CrossRefGoogle Scholar
  48. 48.
    Yu N, Leese GP, Donnan PT (2013) What predicts adverse outcomes in untreated primary hyperparathyroidism? The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol 79:27–34CrossRefGoogle Scholar
  49. 49.
    Andersson P, Rydberg E, Willenheimer R (2004) Primary hyperparathyroidism and heart disease--a review. Eur Heart J 25:1776–1787CrossRefGoogle Scholar
  50. 50.
    Kontogeorgos G, Trimpou P, Laine CM, Olerod G, Lindahl A, Landin-Wilhelmsen K (2015) Normocalcaemic, vitamin D-sufficient hyperparathyroidism - high prevalence and low morbidity in the general population: a long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden. Clin Endocrinol 83:277–284CrossRefGoogle Scholar
  51. 51.
    Suh JM, Cronan JJ, Monchik JM (2008) Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? AJR Am J Roentgenol 191:908–911CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2018

Authors and Affiliations

  1. 1.Medical SchoolAristotle University of ThessalonikiThessalonikiGreece
  2. 2.Department of Endocrinology & Diabetes251 Hellenic Air Force & VA General HospitalAthensGreece
  3. 3.First Department of Pharmacology, Medical SchoolAristotle University of ThessalonikiThessalonikiGreece
  4. 4.Department of Endocrinology & Metabolism424 General Military HospitalN. Efkarpia, ThessalonikiGreece

Personalised recommendations